Literature DB >> 19203545

Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease.

R Masai1, H Wakui, M Togashi, N Maki, H Ohtani, A Komatsuda, K Sawada.   

Abstract

BACKGROUND: There are three subtypes of monoclonal immunoglobulin deposition disease: light chain deposition disease (LCDD), light and heavy chain deposition disease (LHCDD), and heavy chain deposition disease (HCDD). Although it has been considered that LHCDD is a variant of LCDD, information on clinicopathological features and prognosis in LHCDD is presently limited.
METHODS: We reviewed 5,443 renal biopsies, and evaluated clinicopathological features and outcomes in patients with LHCDD, in comparison with those in patients with LCDD and previously reported patients with HCDD. We also characterized paraprotein deposits in patients with LHCDD.
RESULTS: We identified 6 patients with LHCDD, 6 patients with LCDD, and 1 patient with HCDD. The most common clinicopathological findings in patients with LHCDD were proteinuria, renal insufficiency, and nodular sclerosing glomerulopathy. Three patients had IgG-k deposits and 3 patients had IgG-l deposits. Heavy chain subclass analysis performed in 4 patients showed IgG3 deposits in all patients. Dual immunostaining revealed glomerular colocalization of light and heavy chains. In contrast with LCDD, glomerular C3 and C1q deposits were common findings in LHCDD and HCDD. All patients with LHCDD were treated with steroids and cytotoxic agents, but no effect on proteinuria was observed. Three patients developed end-stage renal disease requiring hemodialysis. The underlying hematological disorders in LHCDD and HCDD were milder than in LCDD. Early renal survival and overall patient survival in our patients appeared to be better in LHCDD than in LCDD.
CONCLUSIONS: There are apparent differences in clinicopathological features and prognosis between LHCDD and LCDD. LHCDD is probably more similar to HCDD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203545     DOI: 10.5414/cnp71009

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Probable light- and heavy-chain deposition disease in a patient with nodular diabetic glomerulosclerosis.

Authors:  Noriko Nakamura; Ritsuko Katafuchi; Izumi Watanabe; Yusuke Kuroki; Itsuko Ishida; Kei Hori
Journal:  CEN Case Rep       Date:  2014-02-13

2.  Natural history and outcome of light chain deposition disease.

Authors:  Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

3.  Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.

Authors:  Lorenzo Cavagna; Vincenzo Sepe; Francesca Bobbio-Pallavicini; Filippo Mangione; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Int Urol Nephrol       Date:  2010-06-18       Impact factor: 2.370

4.  Free light chains injure proximal tubule cells through the STAT1/HMGB1/TLR axis.

Authors:  Rohit Upadhyay; Wei-Zhong Ying; Zannatul Nasrin; Hana Safah; Edgar A Jaimes; Wenguang Feng; Paul W Sanders; Vecihi Batuman
Journal:  JCI Insight       Date:  2020-07-23

5.  Discrete renal deposition of IgM heavy chain and κ light chain in Waldenström macroglobulinemia (IgM-κ).

Authors:  Atsushi Komatsuda; Rie Masai; Masaru Togashi; Hiroshi Ohtani; Kenichi Sawada; Hideki Wakui
Journal:  Clin Kidney J       Date:  2012-10

6.  Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions.

Authors:  Tomomichi Kasagi; Hironobu Nobata; Keisuke Suzuki; Naoto Miura; Shogo Banno; Akiyoshi Takami; Taro Yamashita; Yukio Ando; Hirokazu Imai
Journal:  Intern Med       Date:  2017-01-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.